Laxmi Organic Industries Q2FY26 Concall Decoded: “The Chemical Cocktail of Hope and Hangovers”
1. Opening Hook
In a world where chemical stocks react faster than bromine, Laxmi Organic’s Q2FY26 call was part sermon, part survival tale. Global overcapacity? Check. Supply chain rerouting? Double check. Management’s optimism? Off the charts. Like Arjuna focusing on the eye of the fish, Dr. Rajan insists on cost discipline amid chaos — but this fish is swimming in a tank full of ethyl acetate. Stick around — the real alchemy begins when you mix fluorine dreams with fiscal reality. ☠️
2. At a Glance
Revenue down 9% – Apparently “decline” now means “in line with expectations.”
EBITDA at ₹37 Cr (↓50%) – CFO calls it “stable.” Investors call it something else.
Margins at 5.3% (vs 9.7%) – Squeezed harder than a lemon in a chemical wash.
PAT at ₹11 Cr (vs ₹28 Cr) – Typo turned ₹110 Cr fantasy, later clarified. Dreams are free.
Cash Flow ₹153 Cr – Still breathing thanks to working capital yoga.
Debt/Equity 0.17x – Cleaner than a lab coat, for now.
3. Management’s Key Commentary
“Global chemical industry remains demanding with overcapacity and cost pressures.” (Translation: Everyone’s making too much stuff; we’re all broke together.)
“Specialty business declined 20% due to phase-out of one agrochemical product.” (Translation: Our ‘specialty’ took a specialty hit.)
“Deferred deliveries will move to H2, so expect a rebound.” (Translation: Please don’t dump the stock just yet 😅.)
“Fluorine setup ramping as planned; 40–50% of peak revenue expected this year.” (Translation: Still in the lab, but the flask is bubbling.)
“Capex of ₹1,100 Cr remains on track, funded prudently.” (Translation: We’re spending big, but let’s call it ‘vision’.)
“Dahej Phase 1 started production; Phase 2 by Q4.” (Translation: Phase 3—profit—remains a mystery.)
“Cost controls have improved; expenses down 5% YoY.” (Translation: Trimming costs, not bonuses.) 💰
“Partnership with Hitachi Energy for eco gas EconiQ finalized.” (Translation: We’ve found a global friend with deep pockets.)
4. Numbers Decoded
Metric
Q2 FY26
YoY Change
One-Line Analysis
Revenue
₹700 Cr
↓9%
Specialty drag and price moderation did the damage.
EBITDA
₹37 Cr
↓50%
Margins evaporated faster than acetone.
EBITDA Margin
5.3%
↓440 bps
Efficiency talk didn’t reach the bottom line.
PAT
₹11 Cr
↓60%
Profit played peekaboo again.
Gross Margin
33.1%
↓2.7 pts
Product mix hit; “specialty” lost its edge.
Cash Flow from Operations
₹153 Cr
Flat
The one molecule still stable.
Debt/Equity
0.17x
—
Still debt-lite, unlike peers.
Quick Take: Numbers scream “maintenance mode.” Specialty fell, Essentials stagnated, and fluorine’s still a lab experiment.
5. Analyst Questions
Q: Deferred shipments—how much? A: “We can’t share that; it’s competitive.” (Translation: It’s small enough to hide.)
Q: Specialty margins back to 25% soon? A: “FY27 maybe.” (Translation: Not before elections.)
